TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Statins in Children With Type 1 Diabetes and Hypercholesterolemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:Project 1~* T1DM diagnosed clinically for \> 1 year~* any HbA1C~* on stable insulin therapy~* Ages: 10 - 20 years~* both genders~* BMI \< 85th percentile~* Fasting LDL-C\>100mg/dl~* Normal thyroid function~Inclusion Criteria:Projects 2 and 3~* T1DM diagnosed clinically for \> 3 year~* HbA1C \> 8%~* on stable insulin therapy~* Ages: 12- 20 years~* both genders~* BMI \< 85th percentile~* Fasting LDL-C\>100mg/dl~* Normal thyroid function~Exclusion Criteria:Projects 1,2 and 3~* Severe dyslipidemia (LDL-C \>160, TG \> 400 mg/dl)~* Smoking~* Pregnancy~* Current use of anti-inflammatory or immunomodulatory drugs, lipid lowering, antidiabetic drugs~* Patients with hypertension and/or microalbuminuria will be allowed using balanced randomization and standardized treatment

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 20 Years
- Healthy Volunteers: t

Study Arms:
- Atorvastatin (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Observational Study in Patients With Schizophrenia Treated With Long-Acting Risperidone Injection (RISPERDAL CONSTA)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients had schizophrenia (disorganized, catatonic, paranoid, residual, or undifferentiated) that met disease diagnostic criteria as defined in Diagnostic and Statistical Manual of Mental Disorders IV (\[DSM-IV\]~* Requiring new treatment with long-acting risperidone injectable~* Patients were cooperative, reliable, and able to complete all aspects of the protocol~Exclusion Criteria:~* Use of an investigational drug in the past 30 days~* At risk to self or others

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with schizophrenia (Type: None): Long-acting injectable of risperidone given as per the prescription from the prescribing physician (Observational study).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Quadruple Versus Sequential Therapy for Helicobacter Pylori Eradication

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients with age 18 or above, diagnosed to have gastric HP infection~Exclusion Criteria:~* Patients with age less than 18, with past allergy to the study medications, concurrent critical illnesses, a history of previous upper gastrointestinal surgery, intake of nonsteroidal anti-inflammatory drugs, antibiotics, probiotics, bismuth preparation, proton pump inhibitors, anticoagulants or steroids in the previous one month, pregnant or breast-feeding women, drug abusers or alcoholic, history of previous H. Pylori treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sequential therapy (Type: EXPERIMENTAL): Esomeprazole 20mg bid for 10 days, amoxicillin 1g bid for first 5 days, clarithromycin 500mg bid for last 5 days and metronidazole 400mg qid for last 5 days
- Quadruple therapy (Type: ACTIVE_COMPARATOR): Esomeprazole 20mg bid, metronidazole 400mg aid, bismuth sub citrate 120mg aid and tetracycline 500mg qid, all for 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Referred for a clinically indicated pharmacological stress SPECT myocardial perfusion imaging study~Exclusion Criteria:~* Any condition precluding the safe administration of Adenoscan for a SPECT myocardial perfusion imaging study~* Pregnant or breast-feeding, or (if pre-menopausal), not practicing acceptable method of birth control

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Regadenoson
- 2 (Type: ACTIVE_COMPARATOR): Adenoscan

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Safety and Immunogenicity of Simultaneously Administration of sIPV and DTaP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* subjects aged 3 months old at the date of recruitment;~* with informed consent signed by parent(s) or guardians;~* parent(s) or guardians are able to attend all planned clinical appointments and~* obey and follow all study instructions;~* subjects have not been vaccinated with IPV vaccine, OPV vaccine, DTP vaccine and related vaccines;~Exclusion Criteria:~* subject who has a medical history with hypersensitiveness, eclampsia, epilepsy, cerebropathy and neurological illness;~* allergic to any ingredient of vaccine or with allergy history to any vaccine;~* subjects with immunodeficiency or suspected impairment of immunologic function (e.g. caused by HIV), or subjects are in the process of immunosuppressor therapy(Taking orally injecting of steroid hormone);~* administration of immunoglobulins within 30 days prior to this study;~* acute febrile disease(temperature ≥ 37.0°C) or infectious disease;~* have a clearly diagnosed history of thrombocytopenia or other coagulopathy,~* may cause contraindications for subcutaneous injection;~* any serious chronic illness, acute infectious diseases, or respiratory diseases;~* severe cardiovascular disease, liver and kidney diseases or diabetes mellitus with complications;~* any kind of infectious, purulent, or allergic skin diseases;~* any other factor that makes the investigator determines the subject is unsuitable for this study.

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 3 Months
- Healthy Volunteers: t

Study Arms:
- Sabin-IPV and DTaP (Type: EXPERIMENTAL): 234 subjects are simultaneously administrated with Sabin-IPV and DTaP at the age of 3/4/5 months old, 0.5 ml each dose, respectively
- Sabin-IPV only (Type: ACTIVE_COMPARATOR): 234 subjects are administrated with Sabin-IPV only at the age of 3/4/5 months old, 0.5 ml each dose, respectively
- DTaP only (Type: ACTIVE_COMPARATOR): 234 subjects are administrated with DTaP only at the age of 3/4/5 months old, 0.5 ml each dose, respectively

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cortisone Treatment for the Prevention of Postoperative Pancreatitis and Pancreatitis-induced Complications After Pancreaticoduodenectomy and Distal Pancreatic Resection

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Pancreaticoduodenectomy and distal pancreatectomy patients in Tampere University Hospital~Exclusion Criteria:~* Patients with an ongoing cortisone treatment~* Cefuroxime allergy~* Chronic pancreatitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Characterizing Wheelchair-Related Falls in Elderly Veterans

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* veteran~* aged 62 and older~* use a wheelchair for their primary means of mobility~* have used a wheelchair for at least 12 months previous to enrollment~* will be using a wheelchair for at least the next 12 months~Exclusion Criteria:~* not living in a community-based setting~* no access to a telephone

- Gender: ALL
- Minimum Age: 62 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: None): Older veterans who use a wheelchair for their primary means of mobility.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Endometrial Safety Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal women between 40 and 65 years of age with hormone therapy indication (symptoms and need for treatment)~* Non-hysterectomized women.~Exclusion Criteria:~* Usual exclusion criteria for hormone therapy apply.

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 0.25mg DRSP / 0.5mg E2 (BAY86-4891) (Type: EXPERIMENTAL): One capsule \[0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 13 cycles (28 days per cycle).
- 0.5mg NETA / 1.0mg E2 (Activella) (Type: ACTIVE_COMPARATOR): One capsule \[0.5mg norethisterone acetate/1.0mg 17β-estradiol (NETA/E2)\] per day taken orally for 13 cycles (28 days per cycle).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Participant who completed the previous double-blind placebo-controlled study EFC6049 and who did not meet criteria for treatment withdrawal.~* Willingness to participate in a long-term safety/efficacy trial.~Exclusion Criteria:~* Any known condition or circumstance that would prevent in the investigator's opinion, compliance or completion of the study.~The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Placebo/Teriflunomide 7 mg (Type: EXPERIMENTAL): Participants who completed treatment of placebo (for teriflunomide) tablet once daily (QD) for 108 weeks in EFC6049 study, received teriflunomide tablet 7 mg QD for 288 weeks in this extension study.
- Teriflunomide 7 mg/7 mg (Type: EXPERIMENTAL): Participants who completed treatment of teriflunomide 7 mg tablet QD for 108 weeks in EFC6049 study, continued their treatment with teriflunomide 7 mg tablet QD for 288 weeks in this extension study.
- Placebo/Teriflunomide 14 mg (Type: EXPERIMENTAL): Participants who completed treatment of placebo (for teriflunomide) tablet QD for 108 weeks in EFC6049, study received teriflunomide 14 mg tablet QD for 288 weeks in this extension study.
- Teriflunomide 14 mg/14 mg (Type: EXPERIMENTAL): Participants who completed treatment of teriflunomide 14 mg tablet QD for 108 weeks in EFC6049 study, continued their treatment with teriflunomide 14 mg tablet QD for 288 weeks in this extension study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study in Adults With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have Type 2 Diabetes Mellitus based on the disease diagnostic criteria World Health Organization (WHO) classification~* Have been taking at least 2 types of oral diabetes medications for at least 12 weeks prior to entering the study~* Have a Hemoglobin A1c value greater than or equal to 7.0 percent and less than or equal to 11.0 percent if insulin naive If previously on Lantus, then Hemoglobin A1c must be less than or equal to 11.0 percent~* Have a body mass index of less than or equal to 45 kilogram per meter squared (kg/m\^2)~Exclusion Criteria:~* Have significant liver, cardiac or gastrointestinal disease~* Have active cancer or have had cancer within the past 5 years (with the exception of basal cell carcinoma or carcinoma in situ)~* Have an excessive resistance to insulin or hypersensitivity to Lantus~* Have had more than one episode of severe low blood sugar (defined as needing someone else to help because you had very low blood sugar) within the 6 months before entering the study~* Have taken any other insulin other than Lantus within the past 30 days~* Taking any other diabetes medicines that are not allowed in the study or not approved to be taken with insulin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LY2963016 + OAMs (Type: EXPERIMENTAL): LY2963016 titrated based on blood glucose readings, administered subcutaneously, once daily in combination with at least 2 oral antihyperglycemic medications (OAMs) \[alpha glucosidase inhibitors (AGI), dipeptidyl peptidases intravenous (DPP-IV), meglitinide (MEG), metformin (MET), sulfonylurea (SU), and thiazolidinedione (TZD)\] administered per standard of care for 24 weeks
- Lantus + OAMs (Type: ACTIVE_COMPARATOR): Lantus titrated based on blood glucose readings, administered subcutaneously, once daily in combination with at least 2 OAMs (AGI, DPP-IV, MEG, MET, SU, and TZD) administered per standard of care for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus (T2DM)~* Treated with either stable dose of metformin alone \> or = to 1500mg/day or stable dose of insulin \> or = to 30 units/day and up to 2 OAD medications for at least 8 weeks~* Hemoglobin A1c (HbA1c) 7.5% to 10.5% at screening~* Body mass index (BMI) \< or = to 45 kg/m2~Exclusion Criteria:~* For patients who enter the study taking a stable dose of metformin, history of taking OAD medications other than metformin during the 8 weeks prior to screening or have been on insulin therapy within 1 year of screening~* For patients who enter the study taking insulin, history of taking any other therapy outside of the stable insulin and up to 2 OAD medications for 8 weeks prior to screening.~* Use of sulfonylureas during the 8 weeks prior to screening~* Prior exposure to dapagliflozin or any sodium-glucose co-transporter 2 (SGLT-2) inhibitor~* Ingestion of any medication know to affect glucose metabolism for \>7 consecutive days during the 3 months prior to screening~* Ingestion of prescription or over the counter weight loss medication during 3 months prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Farxiga with metformin or insulin (Type: EXPERIMENTAL): Farxiga with metformin (\>/=1500mg/day) or insulin (\>/=30 units/day) and up to 2 OAD medications
- Placebo with metformin or insulin (Type: PLACEBO_COMPARATOR): Placebo with metformin (\>/=1500mg/day) or insulin (\>/=30 units/day) and up to 2 OAD medications

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Meet ARA criteria for diagnosis of RA with active disease.~* RA diagnosis for at least 1 year.~* \> = 6 swollen joints.~* \> = 8 tender joints.~* Taking methotrexate (MTX) or MTX plus not more than 1 added oral DMARD for \> = 3 months and stable for 28 days prior to dosing.~Exclusion Criteria:~* Serious acute or bacterial infection in last 3 months.~* Chronic or recurrent bacterial infections.~* History of TB within previous 3 years or old TB not adequately treated.~* Specific lab test abnormalities~* History of cancer within 5 years.~* Exposure to CTLA4Ig (Cytotoxic T-lymphocyte (T-cell)-associated antigen 4Ig), belatacept, rituximab, efalizumab, alefacept, or other investigational drug or biologic.~* Treatment with hydroxychloroquine, azathioprine, leflunomide, immunoadsorption columns, mycophenolate mofetil, cyclosporine, D-Penicillamine or calcineurin inhibitors.~* Exposure to live vaccines.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (weight < 60 kg) (Type: PLACEBO_COMPARATOR): None
- Group 2 (weight < 60 kg) (Type: PLACEBO_COMPARATOR): None
- Group 3 (weight 60-100 kg) (Type: PLACEBO_COMPARATOR): None
- Group 4 (weight > 100 kg) (Type: PLACEBO_COMPARATOR): None
- Group 5 (weight > 100 kg) (Type: PLACEBO_COMPARATOR): None
- Abatacept (Type: EXPERIMENTAL): Long Term

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Clinically confirmed multiple sclerosis \[MS\];~* Expanded Disability Status Scale \[EDSS\] score less or equal to 6;~* Two documented relapses in the previous 3 years, and one clinical relapse during the preceding year;~* Screening magnetic resonance imaging \[MRI\] scan fulfilling the criteria for a diagnosis of MS.~Exclusion Criteria:~* Clinically relevant cardiovascular, hepatic, hematologic, neurological, endocrine or other major systemic disease;~* Pregnant or nursing woman;~* Wish to parent children during the trial or following the trial (men and women were required to practice effective contraception during the trial and for 24 months after drug discontinuation);~* Prior treatment with interferon \[IFN\], gamma-globulin, glatiramer acetate, or other noncorticosteroid immunomodulatory therapies in the 4 months prior to the trial;~* Use of cladribine, mitoxantrone, or other immunosuppressant agents such as azathioprine, cyclophosphamide, cyclosporin, methotrexate or mycophenolate before enrollment;~* Any known condition or circumstance that would prevent in the investigator's opinion compliance or completion of the study.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (for teriflunomide),~* two tablets once daily for 1 week then,~* one tablet once daily for 35 weeks.
- Teriflunomide 7 mg (Type: EXPERIMENTAL): Teriflunomide 7 mg:~* two tablets once daily for 1 week then,~* one tablet once daily for 35 weeks.
- Teriflunomide 14 mg (Type: EXPERIMENTAL): Teriflunomide 14 mg:~* two tablets once daily for 1 week then,~* one tablet once daily for 35 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Controlled-Release Oxycodone Versus Naproxen at Home After Ambulatory Surgery: A Randomized Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients scheduled for painful ambulatory surgery (knee arthroscopy, unilateral open or laparoscopic inguinal hernia repair)~* American Society of Anesthesiologists (ASA) physical classification I or II~Exclusion Criteria:~* cognitive impairment,~* preoperative pharmacologic pain treatment~* allergy to or a contraindication for taking the study medication (e.g. paracetamol, oxycodone, naproxen or another NSAID)~* porphyria~* pregnancy or lactation~* history of severe renal, hepatic, pulmonary, or cardiac failure~* current symptoms or history of gastrointestinal bleeding, ileus or chronic obstipation~* history of substance abuse, or use of medication with a suppressive effect on the central nervous system

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- PCM/NAPR group (Type: NO_INTERVENTION): paracetamol 1000 mg orally four times a day for 48 hours postoperatively and naproxen 500 mg orally twice a day for 48 hours postoperatively (standard hospital pain protocol for treatment of acute postoperative pain at home after painful day-case surgery)
- PCM/Oxy1 group (Type: ACTIVE_COMPARATOR): Controlled Release oxycodone 10 mg orally twice a day for 24 hours and paracetamol 1000 mg orally four times a day for 48 hours postoperatively
- PCM/Oxy2 group (Type: ACTIVE_COMPARATOR): CR oxycodone 10 mg orally twice a day for 48 hours and paracetamol 1000 mg orally four times a day for 48 hours postoperatively

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete